10-Q: AtriCure Reports 15.8% Revenue Growth in Second Quarter 2024, Driven by Key Product Lines

Sentiment:

Quarterly Report 31 July 2024 11:39 AM

AtriCure's second quarter 2024 results show a strong 15.8% increase in global revenue, fueled by growth across key product lines and strategic initiatives.

Worse than expectedThe company's net loss of $21.277 million for the first six months of 2024 is worse than the net loss of $11.594 million for the same period in 2023.The gross margin decreased by 77 basis points for the first six months of 2024, indicating a decline in profitability.

Summary

AtriCure's global revenue for the six months ended June 30, 2024, reached $225.12 million, a 15.8% increase compared to the same period in 2023.
The company experienced growth across key product lines, including open ablation, minimally invasive ablation, pain management, and appendage management.
In the United States, revenue growth was driven by the ENCOMPASS clamp in open ablation, the AtriClip FlexV for appendage management, and the cryoSPHERE+ probe for pain management.
International sales increased by 29.4% in the second quarter and 25.6% for the six-month period, with strength across all franchises and most major markets.
Gross margin decreased by 168 basis points in the second quarter and 77 basis points for the six-month period, primarily due to unfavorable geographic and product mix, as well as increased product costs.
Research and development expenses increased by 17.1% in the second quarter and 22.9% for the six-month period, driven by expansion of product development, clinical, and regulatory teams, and increased clinical trial expenses.
Selling, general, and administrative expenses increased by 15.4% in the second quarter and 17.8% for the six-month period, primarily due to increased personnel costs and marketing activities.
The company reported a net loss of $8.008 million for the three months ended June 30, 2024, and a net loss of $21.277 million for the six months ended June 30, 2024.
AtriCure had cash, cash equivalents, and investments of $114.02 million and outstanding debt of $61.865 million as of June 30, 2024.

Sentiment

Score: 6

Explanation: The document presents a mixed picture. While revenue growth is strong and there are positive developments in product innovation and clinical trials, the increased net loss and decreased gross margin temper the overall sentiment. The company is facing increased competition and legal challenges, which add to the uncertainty.

Positives

Strong global revenue growth of 15.8% year-over-year for the first six months of 2024.
Successful launch of the cryoSPHERE+ probe in the US market.
Gained regulatory approval in China for the AtriClip system.
FDA clearance for the EPi-Ease hybrid access device.
Significant progress in the LeAAPS clinical trial with over 2,700 patients enrolled.
Strong international sales growth of 25.6% for the first six months of 2024.
The company has a new credit facility with significant unused borrowing capacity.

Negatives

Gross margin decreased by 77 basis points for the first six months of 2024.
The company reported a net loss of $21.277 million for the first six months of 2024.
Research and development expenses increased by 22.9% for the first six months of 2024.
Selling, general, and administrative expenses increased by 17.8% for the first six months of 2024.

Risks

Increased competition in key markets may cause variability in results.
The company is subject to legal proceedings, including a False Claims Act investigation and a lawsuit alleging illegal kickbacks.
The company's future capital requirements depend on various factors, including market acceptance of products, regulatory changes, and clinical trial costs.
Macroeconomic conditions, such as inflationary pressures, rising interest rates, and currency fluctuations, may impact liquidity and access to capital resources.

Future Outlook

The company anticipates that substantially all of its revenue for the foreseeable future will relate to products it currently sells or is in the process of developing. They continue to invest in product innovation, clinical science, and physician education to expand awareness and adoption.

Management Comments

In 2024, we realized strong global revenue growth and continued our strategic initiatives of product innovation, clinical science and physician education and training to expand awareness and adoption.
Our worldwide revenue for the six months ended June 30, 2024 was $225,120, representing an increase of $30,708, or 15.8%, over the first six months of 2023, driven by growing adoption across key product lines.

Industry Context

The company is seeing new entrants developing competing products, procedures, and/or clinical solutions that may cause variability in results. The company is a leading innovator in treatments for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management.

Comparison to Industry Standards

The document does not provide specific competitor data for direct comparison.
The company's revenue growth of 15.8% is a positive indicator, but the decrease in gross margin and net loss need to be considered in the context of industry benchmarks.
The company's investment in R&D and clinical trials is consistent with industry trends for medical device companies focused on innovation.
The company's new credit facility provides financial flexibility, which is important for growth and expansion.

Corporate Governance

Change Type	Description	Effective Date	Impact Assessment
Bylaw Amendment	The Board of Directors approved the Amended and Restated Bylaws of AtriCure, Inc. which include updates and changes related to the manner of providing notice of stockholder meetings, the adjournment of stockholder meetings, the list of stockholders entitled to vote at stockholder meetings, and stock certificates.	2024-07-30	The changes are intended to reflect and conform to the current provisions of the Delaware General Corporation Law (the DGCL) and clarify the authority of a stockholder meeting chair to adopt and enforce rules and regulations for the conduct of stockholder meetings.
Bylaw Amendment	Stockholders soliciting proxies must use a proxy card color other than white, which shall be reserved for the exclusive use of the Board.	2024-07-30	This change is intended to ensure clarity and order in proxy solicitations.
Bylaw Amendment	For a person to be qualified to stand for election or re-election as a director, the person is required to timely deliver, or cause to be delivered, to the secretary of the Company both (i) such persons written consent to be named in a proxy statement relating to the meeting of stockholders at which directors are to be elected and (ii) a completed and signed questionnaire with respect to background, qualifications, stock ownership and independence.	2024-07-30	This change is intended to ensure that all director candidates meet the necessary qualifications and provide required information.
Bylaw Amendment	For a person nominated by a stockholder to be qualified to stand for election or re-election as a director, the nominating stockholder must timely deliver to the secretary of the Company certain representations, to ensure compliance with the applicable requirements of Rule 14a-19 under the Securities Exchange Act of 1934, as amended and, if such stockholder, any beneficial owner on whose behalf the nomination is submitted or any person who controls either of the foregoing stockholder or beneficial owner, directly or indirectly, acts contrary to any such representations, such nominee will be disqualified from standing for election or re-election as a director.	2024-07-30	This change is intended to ensure compliance with SEC regulations regarding proxy solicitations.
Bylaw Amendment	Revisions to the indemnification and advancement provisions to, among other things, (i) clarify that the Company shall, to the fullest extent permitted by applicable law, indemnify, and advance expenses incurred in defending a proceeding to, any person who was or is made a party or threatened to be made a party to any proceeding by reason of the fact that he or she is or was a director or an officer of the Company or, while serving as a director or officer of the Company, is or was serving at the request of the Company as a director, officer, employee or agent of another entity, (ii) clarify that the prohibition on indemnification in connection with a proceeding initiated by an indemnitee does not apply to a proceeding, or part thereof, initiated to enforce a right to indemnification or advancement or a compulsory counterclaim, and (iii) provide than an indemnitee can bring an action to enforce a right to advancement of expenses if a claim therefor is not paid in full within 20 days.	2024-07-30	These changes are intended to clarify and strengthen the indemnification and advancement rights of directors and officers.
Bylaw Amendment	The Delaware Court of Chancery shall be the sole and exclusive forum for any stockholder to bring certain actions, including, without limitation, derivative actions, claims for breach of fiduciary duty, claims arising under the DGCL, claims governed by the internal affairs doctrine, and actions in the right of the Company asserting claims as to which the DGCL confers jurisdiction to the Delaware Court of Chancery.	2024-07-30	This change is intended to ensure that certain legal actions are brought in the appropriate jurisdiction.
Bylaw Amendment	The federal district courts of the United States of America shall be the sole and exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act of 1933, as amended.	2024-07-30	This change is intended to ensure that certain legal actions are brought in the appropriate jurisdiction.

Legal Proceedings

The company received a Civil Investigative Demand (CID) from the U.S. Department of Justice (USDOJ) in December 2017 regarding potential violations of the False Claims Act.
The USDOJ investigation is based on a lawsuit brought on behalf of the United States and various state and local governments under the qui tam provisions of federal and certain state and local False Claims Acts.
The relator in the lawsuit alleges that the company paid illegal kickbacks to healthcare providers in exchange for using or referring the company's products.
The company is contesting the case, but the outcome is uncertain.
In May 2023, the company entered into an Assignment and Agreement Regarding IDx and CCF Intellectual property (Assignment Agreement) with Clinic and IDx, which required a one-time payment of $33.4 million for the acquisition of patents and other intellectual property and dismissal of the arbitration and release of payment for royalty obligations due to Clinic and IDx under the License Agreement after March 31, 2023.

Stakeholder Impact

Shareholders may be impacted by the company's net loss and the ongoing legal proceedings.
Employees may be impacted by the company's growth and strategic initiatives.
Customers may benefit from the company's product innovation and training programs.
Suppliers may be impacted by the company's purchase agreements.
Creditors may be impacted by the company's debt and financial performance.

Next Steps

Continue enrollment and site initiation for the LeAAPS clinical trial.
Pursue regulatory approvals for new products globally.
Continue to invest in research and development of new products.
Monitor and manage macroeconomic conditions that may impact liquidity and access to capital resources.

Key Dates

Date	Description
2023-01-01	Start date for competitor comparison data.
2023-05	Agreement to terminate license agreement and royalty payments.
2023-12-31	Expiration of the PMA approval milestone for contingent consideration.
2024-01-05	Date of new credit agreement with JPMorgan Chase Bank, N.A.
2024-06-30	End of the quarterly period for this report.
2024-07-29	Date of outstanding shares calculation.
2024-07-30	Date of approval of Amended and Restated Bylaws.
2026-12-31	Expiration of the achievement period for the reimbursement milestone for contingent consideration.
2027-01-05	Maturity date of the credit agreement.

Keywords

Atrial Fibrillation, Ablation, Left Atrial Appendage Management, Pain Management, Medical Devices, Surgical Treatments, LeAAPS Trial, cryoSPHERE+, AtriClip, EPi-Ease

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.